OvaScience (NASDAQ: OVAS) and Infinity Pharmaceuticals (NASDAQ:INFI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.

Volatility & Risk

OvaScience has a beta of 3.49, meaning that its stock price is 249% more volatile than the S&P 500. Comparatively, Infinity Pharmaceuticals has a beta of 2.8, meaning that its stock price is 180% more volatile than the S&P 500.

Profitability

This table compares OvaScience and Infinity Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OvaScience -20,090.13% -68.71% -60.49%
Infinity Pharmaceuticals N/A -85.61% -59.80%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for OvaScience and Infinity Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OvaScience 1 1 1 0 2.00
Infinity Pharmaceuticals 0 0 1 0 3.00

OvaScience currently has a consensus target price of $8.00, indicating a potential upside of 459.44%. Given OvaScience’s higher possible upside, analysts plainly believe OvaScience is more favorable than Infinity Pharmaceuticals.

Earnings & Valuation

This table compares OvaScience and Infinity Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OvaScience $650,000.00 78.56 -$82.25 million ($1.83) -0.78
Infinity Pharmaceuticals $18.72 million 5.07 -$30.10 million ($1.15) -1.63

Infinity Pharmaceuticals has higher revenue and earnings than OvaScience. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than OvaScience, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

55.1% of OvaScience shares are held by institutional investors. Comparatively, 54.3% of Infinity Pharmaceuticals shares are held by institutional investors. 9.5% of OvaScience shares are held by insiders. Comparatively, 6.8% of Infinity Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

About OvaScience

OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman’s ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman’s own EggPC cells without the need for hormone hyperstimulation.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.